Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations-Reference-Cited by-同舟云学术

Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations

Published:2024-07-08 Issue: Volume: Page:
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Zhou Shuntai¹²^ORCID,Long Nathan¹,Rosenke Kyle³,Jarvis Michael A³⁴⁵,Feldmann Heinz³^ORCID,Swanstrom Ronald¹⁶^ORCID

Affiliation:

1. Lineberger Comprehensive Cancer Center

2. Department of Microbiology and Immunology, University of North Carolina at Chapel Hill

3. Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana

4. School of Biomedical Sciences, University of Plymouth

5. The Vaccine Group Ltd , Plymouth, Devon , United Kingdom

6. Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill

Abstract

Abstract We investigated the mutation profiles of severe acute respiratory syndrome coronavirus 2 in samples collected from a molnupiravir and nirmatrelvir/ritonavir combination therapy in macaques. We found that molnupiravir induced several nirmatrelvir resistance mutations at low abundance that were not further selected in combination therapy. Coadministration of nirmatrelvir/ritonavir lowered the magnitude of the mutagenetic effect of molnupiravir.

Funder

Antiviral Drug Discovery and Development Center

National Institutes of Health

Intramural Research Program of the

National Institute of Allergy and Infectious Diseases

University of North Carolina (UNC) Center for AIDS Research

UNC Lineberger Comprehensive Cancer Center

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiae213/58467959/jiae213.pdf

Reference12 articles.

1. Review: the landscape of antiviral therapy for COVID-19 in the era of widespread population immunity and Omicron-lineage viruses;Meyerowitz;Clin Infect Dis,2023

2. β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells;Zhou;J Infect Dis,2021

3. Lethal mutagenesis as an antiviral strategy;Swanstrom;Science,2022

4. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes;Sanderson;Nature,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm;The Journal of Infectious Diseases;2024-07-08